<?xml version='1.0' encoding='utf-8'?>
<document id="31646831"><sentence text="Drug-drug interactions in patients using tyrosine kinase inhibitors: A multicenter retrospective study."><entity charOffset="41-49" id="DDI-PubMed.31646831.s1.e0" text="tyrosine" /></sentence><sentence text="Tyrosine kinase inhibitors (TKIs) are frequently used drugs in oncology practice"><entity charOffset="0-8" id="DDI-PubMed.31646831.s2.e0" text="Tyrosine" /></sentence><sentence text=" Although oral administration is an advantage, long-term use increases potential drug-drug interaction risk" /><sentence text=" The purpose of this study was to assess the prevalence of potential TKI-drug interaction (PTDI) in patients who used TKIs and increase awareness of this subject" /><sentence text="" /><sentence text="We retrospectively evaluated the data of 310 patients collected from four different oncology centers, where TKIs were administered for solid organ cancer, between January 2007 and December 2017" /><sentence text=" The potential interaction between TKI and any other prescribed drug was determined using ''LexicompÂ® Drug Interactions, App Version 1" /><sentence text="1'' software" /><sentence text="" /><sentence text="Overall, 310 patients were included; among those, 301 (97" /><sentence text="1%) were using another drug with TKI and 147 (47" /><sentence text="4%) experienced PTDI at least once" /><sentence text=" The median number of additional drugs was 4 (range 1-12)" /><sentence text=" We detected 250 PTDIs, of which 30" /><sentence text="8% were major interactions" /><sentence text=" The most frequently interacting TKI was imatinib (29"><entity charOffset="41-49" id="DDI-PubMed.31646831.s16.e0" text="imatinib" /></sentence><sentence text="6%), and the additional drug group was antibiotics (21" /><sentence text="2%)" /><sentence text=" We observed that PTDIs caused the following effects: TKI concentration was increased or decreased owing to 14" /><sentence text="4% or 22" /><sentence text="8% PTDIs, respectively, and electrocardiographic QT prolongation occurred in 22% of all PTDIs" /><sentence text=" Multivariate analysis demonstrated that use of higher number of additional drugs (odds ratio/OR=1" /><sentence text="63), pre-existing lung cancer (OR=8" /><sentence text="82), and use of pazopanib (OR=9"><entity charOffset="16-25" id="DDI-PubMed.31646831.s24.e0" text="pazopanib" /><entity charOffset="27-29" id="DDI-PubMed.31646831.s24.e1" text="OR" /><pair ddi="false" e1="DDI-PubMed.31646831.s24.e0" e2="DDI-PubMed.31646831.s24.e0" /><pair ddi="false" e1="DDI-PubMed.31646831.s24.e0" e2="DDI-PubMed.31646831.s24.e1" /></sentence><sentence text="22) were potential risk factors" /><sentence text="" /><sentence text="The rate of PTDI is quite high in patients using TKIs" /><sentence text=" Effort must be made to increase awareness of this subject" /><sentence text=" Increasing awareness aids in lowering toxicity rates and providing efficient antitumor therapy" /><sentence text="" /></document>